Please login to the form below

Not currently logged in
Email:
Password:

larotrectinib

This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment. Loxo Oncology and Bayer should hear from the FDA about their tumour biomarker-targeted cancer drug larotrectinib by 26 November, after ... TRK inhibitor Larotrectinib is being reviewed by

Latest news

  • Pharma sales help Bayer escape the worst from a bumpy 2017 Pharma sales help Bayer escape the worst from a bumpy 2017

    But those failures were tempered by positive results late in the year for larotrectinib, one of two cancer assets licensed from Loxo Oncology in a $1.5bn deal. ... Larotrectinib is expected to be filed for US approval within the coming weeks, and the

  • Roche buys cancer company Ignyta for $1.7bn Roche buys cancer company Ignyta for $1.7bn

    That high level of response was behind Bayer’s decision to stump up $1.55bn to license Loxo’s larotrectinib, which is also in phase II basket trials involving patients with

  • Bayer gets clinical data to support $1.5bn Loxo deal Bayer gets clinical data to support $1.5bn Loxo deal

    Bayer gets clinical data to support $1.5bn Loxo deal. Larotrectinib’s response rate likely to be practice changing. ... Larotrectinib’s near universal response rate and compelling durability of response in paediatric patients with TRK fusion cancers

  • Joerg Moeller to head Bayer R&D after operational shake-up Joerg Moeller to head Bayer R&D after operational shake-up

    Among the highlights on the agenda are a look at its emerging cancer pipeline, including Loxo-sourced TRK inhibitors larotrectinib and LOXO-195 as well as projects in oncogenic signalling,

  • Loxo’s cancer drug pair attracts $1.5bn deal with Bayer Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

    In the ASCO trials, larotrectinib achieved a 76% objective response rate in 50 patients - both adults and children - diagnosed with 17 types of TRK fusion protein-positive advanced cancer. ... LOXO-195 seems to have activity in cancers that acquire

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics